Enzo Biochem Pre-Tax Profit Margin 2006-2021 | ENZ

Enzo Biochem pre-tax profit margin from 2006 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Enzo Biochem Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-10-31 $0.12B $0.01B 4.31%
2021-07-31 $0.12B $0.01B 5.93%
2021-04-30 $0.11B $0.00B 0.88%
2021-01-31 $0.10B $-0.01B -11.34%
2020-10-31 $0.09B $-0.02B -24.71%
2020-07-31 $0.08B $-0.03B -38.16%
2020-04-30 $0.08B $-0.03B -40.26%
2020-01-31 $0.08B $0.00B 1.25%
2019-10-31 $0.08B $0.00B 1.25%
2019-07-31 $0.08B $0.00B 3.70%
2019-04-30 $0.08B $0.00B 2.41%
2019-01-31 $0.09B $-0.02B -26.14%
2018-10-31 $0.10B $-0.02B -17.89%
2018-07-31 $0.10B $-0.01B -11.88%
2018-04-30 $0.10B $-0.01B -5.83%
2018-01-31 $0.11B $-0.00B -2.86%
2017-10-31 $0.11B $-0.00B -1.90%
2017-07-31 $0.10B $-0.00B -1.92%
2017-04-30 $0.11B $0.04B 33.02%
2017-01-31 $0.11B $0.03B 31.43%
2016-10-31 $0.10B $0.04B 39.42%
2016-07-31 $0.10B $0.05B 45.63%
2016-04-30 $0.10B $0.02B 18.63%
2016-01-31 $0.10B $0.02B 18.00%
2015-10-31 $0.10B $0.01B 7.14%
2015-07-31 $0.10B $-0.00B -2.04%
2015-04-30 $0.10B $-0.01B -14.43%
2015-01-31 $0.10B $-0.01B -11.34%
2014-10-31 $0.10B $-0.01B -11.34%
2014-07-31 $0.10B $-0.01B -10.42%
2014-04-30 $0.09B $-0.01B -11.70%
2014-01-31 $0.09B $-0.02B -18.28%
2013-10-31 $0.09B $-0.02B -20.65%
2013-07-31 $0.09B $-0.02B -21.28%
2013-04-30 $0.10B $-0.05B -46.39%
2013-01-31 $0.10B $-0.04B -42.00%
2012-10-31 $0.10B $-0.04B -38.83%
2012-07-31 $0.10B $-0.04B -38.83%
2012-04-30 $0.10B $-0.02B -14.42%
2012-01-31 $0.10B $-0.01B -13.46%
2011-10-31 $0.10B $-0.02B -15.53%
2011-07-31 $0.10B $-0.01B -12.62%
2011-04-30 $0.10B $-0.02B -14.85%
2011-01-31 $0.10B $-0.02B -17.17%
2010-10-31 $0.10B $-0.02B -21.43%
2010-07-31 $0.10B $-0.02B -22.68%
2010-04-30 $0.10B $-0.02B -21.65%
2010-01-31 $0.10B $-0.02B -21.88%
2009-10-31 $0.09B $-0.02B -20.21%
2009-07-31 $0.09B $-0.02B -25.56%
2009-04-30 $0.09B $-0.02B -25.58%
2009-01-31 $0.08B $-0.02B -24.39%
2008-10-31 $0.08B $-0.02B -20.25%
2008-07-31 $0.08B $-0.01B -14.29%
2008-04-30 $0.07B $-0.01B -13.51%
2008-01-31 $0.07B $-0.01B -17.39%
2007-10-31 $0.06B $-0.01B -20.97%
2007-07-31 $0.05B $-0.01B -24.53%
2007-04-30 $0.05B $-0.02B -33.33%
2007-01-31 $0.04B $-0.02B -36.59%
2006-10-31 $0.04B $-0.02B -37.50%
2006-07-31 $0.04B $-0.02B -42.50%
2006-04-30 $0.04B $-0.02B -36.59%
2006-01-31 $0.04B $-0.01B -33.33%
2005-10-31 $0.04B $-0.01B -23.26%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.154B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00